Delay in Debt-to-Equity Swap for Vietnamese Subsidiary (Neutral)

Acquisition date postponed from 2026.05.15 to 2026.06.15 due to processing delays at Vietnamese authorities
Acquisition amount: KRW 2,979.6 million (7.29% of equity), post-acquisition stake 100%
Target: Dong-Il Interlining, Ltd. (Vietnam, interlining manufacturing, affiliated)
Target financials: Net loss for three consecutive years (current -KRW 923M, prior -KRW 733M, prior-prior -KRW 864M), capital impairment (equity KRW 416M vs. capital stock KRW 5.6B)
Purpose: Improve subsidiary's financial structure
Board meeting: Two outside directors absent; auditor absent

Filing: [Correction of Description] Decision on Acquisition of Stocks and Equity Securities of Other Corporations
Company: GeneOne Life Science (011000)
Submission: GeneOne Life Science, Inc.
Receipt: 05-15-2026
Under KRX KOSPI Market Division